Competitive binding assay for quantitative determination of GM1 ganglioside in plasma and cerebrospinal fluid

Kirschner, G.; Bassan, Michele; Facco, M.P.; Ferrari, Giovanna; Callegaro, L.

doi:10.1016/0731-7085(92)80024-h

Cited by 4 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since a silica surface provides a larger surface area than a regular surface which, in turn, leads to increased adsorption of GM1, microtitration plates coated with silica were used in this assay (Frey et al 1993). In the sample and standard solutions, the GM1 binds speci® cally to the û subunit of cholera toxin conjugated with the horseradish peroxidase (û -CT-HRP) (Holmgren et al 1980;Kirschner et al 1992). When aliquots of the sample and standard solutions are added to the GM1 coated plates, excess û -CT-HRP binds to the GM1.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

GM1 Delivery to the CSF Via the Olfactory Pathway

et al. 1999

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

“…GM1 concentrations were assayed in each of the fractions. GM1 was measured in the CSF using the method of Kirschner et al (1992). This is a competitive immuno-enzymatic assay where the hydrophobic portion of GM1 is adsorbed onto a surface with its hydrophilic end exposed to react with other molecules (Holmgren et al 1980).…”

Section: Methodsmentioning

confidence: 99%

GM1 Delivery to the CSF Via the Olfactory Pathway

et al. 1999

View full text Add to dashboard Cite

“…Aliquots of the homogenates were freeze-dried and stored at -80" C. Extraction and determination were performed with a modification of the method of Kirschner et a1. 16 Ganglioside GM, was extracted three times from 0.5 ml plasma as follows: 2 ml tetrahydrofurane (THF, Merck, Darmstadt, Germany) was mixed with the plasma. The sample was centrifuged and the supernatant collected.…”

Section: Methodsmentioning

confidence: 99%

Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers

Rost

Brockmöller

Weber

et al. 1991

Clin Pharmacol Ther

View full text Add to dashboard Cite

Ganglioside GM1 multiple-dose pharmacokinetics were investigated in five healthy male volunteers. Doses of 100 mg were administered either intravenously or intramuscularly for 21 days, and the washout was followed-up for a further 21 days. The highly specific binding of the beta-subunit of cholera toxin was used to quantify ganglioside GM1 levels in plasma, urine, and feces. This dose regime increased the ganglioside GM1 steady-state plasma levels two to three orders of magnitude above the endogenous levels of 0.132 mg/L (coefficient of variation, 8.9%). Large and variable amounts of ganglioside GM1 were found in feces before and during treatment without relation to the dosage. No ganglioside GM1 could be detected in urine at any time. Plasma kinetics were linear with a biexponential disposition. Exogenously administered ganglioside GM1 was confined mainly to the blood volume as indicated by a steady-state volume of distribution of 6.98 +/- 3.57 L and appears to be excreted mainly in the form of metabolites. The total clearance was very slow at 1.61 +/- 0.37 ml/min. Absorption after intramuscular administration was slow (time to reach maximum concentration greater than 12 hours) and yielded steady-state concentrations somewhat lower compared with the intravenous infusion.

show abstract

Monosialoganglioside GM1 blood levels in maternal and newborn umbilical cord blood at birth

1993

View full text Add to dashboard Cite

Blood levels of the monosialoganglioside GM1 (nomenclature according to Svennerholm) were tested at birth in the umbilical cord of 37 neonates and their mothers. Comparisons were made based on gestational age and modality of delivery. GM1 blood levels at birth were significantly higher in mothers than in newborns (373.66 +/- 56.83 ng/ml vs 217.95 +/- 21.24 ng/ml; P < 0.01). Newborns delivered by cesarean section showed levels of GM1 significantly higher than those delivered vaginally (298.97 +/- 38.55 ng/ml vs 169.62 +/- 12.62 ng/ml; P < 0.01), and preterm newborns had significantly higher levels of GM1 than full-term newborns (253.50 +/- 40.83 ng/ml vs 193.71 +/- 21.74 ng/ml; P < 0.01). No differences in blood levels of GM1 were observed in the mothers in relation to length of pregnancy or modality of delivery. The higher levels of GM1 observed in preterm newborns indicate an increased turnover and/or enhanced bioavailability of the monosialoganglioside GM1 for the developing central nervous system. Further data are required to evaluate the significance of the increased cord levels of GM1 in neonates after cesarean section.

show abstract

Competitive binding assay for quantitative determination of GM1 ganglioside in plasma and cerebrospinal fluid

Cited by 4 publications

References 30 publications

GM1 Delivery to the CSF Via the Olfactory Pathway

GM1 Delivery to the CSF Via the Olfactory Pathway

Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers

Monosialoganglioside GM1 blood levels in maternal and newborn umbilical cord blood at birth

Contact Info

Product

Resources

About